Key Points
- VP Jeffrey Zerillo sold 1,000 shares on February 11 at an average price of $65.93 for $65,930, leaving him with 41,048 shares — a 2.38% reduction in his ownership.
- Prestige missed quarterly estimates with EPS $1.14 vs. $1.16 expected and revenue $283.44M (down 2.4% YoY), set FY2026 guidance at 4.54 EPS, and carries an analyst consensus of "Hold" with an average target of $80.60.
Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares of the company's stock, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Jeffrey Zerillo also recently made the following trade(s):
- On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total value of $16,860.00.
- On Friday, November 28th, Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $60.00, for a total value of $43,140.00.
Prestige Consumer Healthcare Stock Performance
NYSE:PBH opened at $66.81 on Friday. The firm's fifty day simple moving average is $63.81 and its 200-day simple moving average is $63.71. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The stock has a market cap of $3.16 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 2.11 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to analysts' expectations of $286.93 million. During the same period in the prior year, the firm posted $1.22 EPS. The firm's quarterly revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a "buy" rating for the company in a report on Friday, November 7th. Weiss Ratings restated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group reduced their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a research note on Friday, January 30th. Oppenheimer cut their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an "outperform" rating for the company in a report on Tuesday, October 21st. Finally, Zacks Research raised Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research note on Monday, November 10th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Hold" and an average target price of $80.60.
Get Our Latest Analysis on PBH
Hedge Funds Weigh In On Prestige Consumer Healthcare
Several large investors have recently added to or reduced their stakes in PBH. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company's stock worth $100,893,000 after acquiring an additional 70,376 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at approximately $1,890,000. AXQ Capital LP purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at approximately $694,000. Tributary Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company's stock worth $23,675,000 after purchasing an additional 231,969 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Prestige Consumer Healthcare by 51.8% in the second quarter. Franklin Resources Inc. now owns 33,476 shares of the company's stock valued at $2,673,000 after purchasing an additional 11,429 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.
Prestige Consumer Healthcare Company Profile
(
Get Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
